These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

464 related articles for article (PubMed ID: 8844631)

  • 1. A comparison of the effects of oral conjugated equine estrogen and transdermal estradiol-17 beta combined with an oral progestin on quality of life in postmenopausal women.
    Hilditch JR; Lewis J; Ross AH; Peter A; van Maris B; Franssen E; Charles J; Norton P; Dunn EV
    Maturitas; 1996 Jul; 24(3):177-84. PubMed ID: 8844631
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A double-blind, randomized, comparative study evaluating clinical effects of two sequential estradiol-progestogen combinations containing either desogestrel or medroxyprogesterone acetate in climacteric women.
    Saure A; Planellas J; Poulsen HK; Jaszczak P
    Maturitas; 2000 Feb; 34(2):133-42. PubMed ID: 10714908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Continuous versus cyclical transdermal estrogen replacement therapy in postmenopausal women: influence on climacteric symptoms, body weight and bleeding pattern.
    Lübbert H; Nauert C
    Maturitas; 1997 Dec; 28(2):117-25. PubMed ID: 9522319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group.
    Hulley S; Grady D; Bush T; Furberg C; Herrington D; Riggs B; Vittinghoff E
    JAMA; 1998 Aug; 280(7):605-13. PubMed ID: 9718051
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of transdermal 17 beta-estradiol and oral conjugated equine estrogens on biochemical parameters of bone resorption in natural menopause.
    Reginster JY; Christiansen C; Dequinze B; Deroisy R; Gaspard U; Taquet AN; Franchimont P
    Calcif Tissue Int; 1993 Jul; 53(1):13-6. PubMed ID: 8394191
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HRT and exercise: effects on bone density, muscle strength and lipid metabolism. A placebo controlled 2-year prospective trial on two estrogen-progestin regimens in healthy postmenopausal women.
    Heikkinen J; Kyllönen E; Kurttila-Matero E; Wilén-Rosenqvist G; Lankinen KS; Rita H; Väänänen HK
    Maturitas; 1997 Mar; 26(2):139-49. PubMed ID: 9089564
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial.
    Rapp SR; Espeland MA; Shumaker SA; Henderson VW; Brunner RL; Manson JE; Gass ML; Stefanick ML; Lane DS; Hays J; Johnson KC; Coker LH; Dailey M; Bowen D;
    JAMA; 2003 May; 289(20):2663-72. PubMed ID: 12771113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of oral and transdermal hormone replacement therapy on internal carotid artery pulsatility indices in postmenopausal women. A prospective, randomized, comparative study.
    Sendağ F; Terek MC; Karadadaş N; Bilgin O
    J Reprod Med; 2001 Nov; 46(11):962-8. PubMed ID: 11762152
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized, double-blind, multicentre study comparing the clinical effects of two sequential estradiol-progestin combinations containing either desogestrel or norethisterone acetate in climacteric women with estrogen deficiency symptoms.
    Saure A; Hirvonen E; Milsom I; Christensen A; Damber MG
    Maturitas; 1996 May; 24(1-2):111-8. PubMed ID: 8794442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential prevalence of quality-of-life categories (domains) in Asian women and changes after therapy with three doses of conjugated estrogens/medroxyprogesterone acetate: the Pan-Asia Menopause (PAM) study.
    Limpaphayom KK; Darmasetiawan MS; Hussain RI; Burriss SW; Holinka CF; Ausmanas MK
    Climacteric; 2006 Jun; 9(3):204-14. PubMed ID: 16766434
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of oral and transdermal hormone replacement therapy on lipid profile and Lp(a) level in menopausal women with hypercholesterolemia.
    Perrone G; Stefanutti C; Galoppi P; Anelli G; Capri O; Lucani G; Vivenzio A; Mazzarella B; Zichella L
    Int J Fertil Menopausal Stud; 1996; 41(6):509-15. PubMed ID: 9010744
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of Oral vs Transdermal Estrogen Therapy on Sexual Function in Early Postmenopause: Ancillary Study of the Kronos Early Estrogen Prevention Study (KEEPS).
    Taylor HS; Tal A; Pal L; Li F; Black DM; Brinton EA; Budoff MJ; Cedars MI; Du W; Hodis HN; Lobo RA; Manson JE; Merriam GR; Miller VM; Naftolin F; Neal-Perry G; Santoro NF; Harman SM
    JAMA Intern Med; 2017 Oct; 177(10):1471-1479. PubMed ID: 28846767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Percutaneous estradiol/oral micronized progesterone has less-adverse effects and different gene regulations than oral conjugated equine estrogens/medroxyprogesterone acetate in the breasts of healthy women in vivo.
    Murkes D; Lalitkumar PG; Leifland K; Lundström E; Söderqvist G
    Gynecol Endocrinol; 2012 Oct; 28 Suppl 2():12-5. PubMed ID: 22834417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Symptom relief and side effects of postmenopausal hormones: results from the Postmenopausal Estrogen/Progestin Interventions Trial.
    Greendale GA; Reboussin BA; Hogan P; Barnabei VM; Shumaker S; Johnson S; Barrett-Connor E
    Obstet Gynecol; 1998 Dec; 92(6):982-8. PubMed ID: 9840563
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quality of life assessment in a chemoprevention trial: fenretinide and oral or transdermal HRT.
    Serrano D; Mariani L; Mora S; Guerrieri-Gonzaga A; Cazzaniga M; Daldoss C; Ramazzotto F; Feroce I; Decensi A; Bonanni B
    Maturitas; 2006 Aug; 55(1):69-75. PubMed ID: 16500052
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial.
    Shumaker SA; Legault C; Rapp SR; Thal L; Wallace RB; Ockene JK; Hendrix SL; Jones BN; Assaf AR; Jackson RD; Kotchen JM; Wassertheil-Smoller S; Wactawski-Wende J;
    JAMA; 2003 May; 289(20):2651-62. PubMed ID: 12771112
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Menopausal symptoms and treatment-related effects of estrogen and progestin in the Women's Health Initiative.
    Barnabei VM; Cochrane BB; Aragaki AK; Nygaard I; Williams RS; McGovern PG; Young RL; Wells EC; O'Sullivan MJ; Chen B; Schenken R; Johnson SR;
    Obstet Gynecol; 2005 May; 105(5 Pt 1):1063-73. PubMed ID: 15863546
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of hormone therapy on bone mineral density: results from the postmenopausal estrogen/progestin interventions (PEPI) trial. The Writing Group for the PEPI.
    JAMA; 1996 Nov; 276(17):1389-96. PubMed ID: 8892713
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of continuous combined hormone replacement therapy on inflammation in hypertensive and/or overweight postmenopausal women.
    Koh KK; Ahn JY; Jin DK; Yoon BK; Kim HS; Kim DS; Shin MS; Son JW; Choi IS; Shin EK
    Arterioscler Thromb Vasc Biol; 2002 Sep; 22(9):1459-64. PubMed ID: 12231566
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mammographic breast density during hormone replacement therapy: effects of continuous combination, unopposed transdermal and low-potency estrogen regimens.
    Lundström E; Wilczek B; von Palffy Z; Söderqvist G; von Schoultz B
    Climacteric; 2001 Mar; 4(1):42-8. PubMed ID: 11379377
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.